https://www.selleckchem.com/pr....oducts/beta-lapachon
This will be the first study to evaluate the add-on effect of PCSK9i on endothelial function of T2DM patients under regular use of empagliflozin. ClinicalTrials.gov identifier NCT03932721. ClinicalTrials.gov identifier NCT03932721. In Taiwan, approximately 90% of patients with end-stage renal disease receive maintenance hemodialysis. Although studies have reported the survival predictability of multiclinical factors, the higher-order interactions among these factors have rarely been discussed. Conventional statistical approaches
Like
Comment
Share
